Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
175.2 SEK | +5.80% | +11.17% | -10.02% |
May. 02 | Vitrolife to Acquire Dutch Company eFertility | MT |
May. 02 | Vitrolife AB (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for ?18 million. | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 42.33 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.02% | 2.06B | B- | ||
-1.89% | 12.5B | B+ | ||
-9.59% | 7.67B | B- | ||
+21.82% | 5.36B | C | ||
-1.31% | 5.26B | B | ||
+0.02% | 4.57B | C | ||
-50.89% | 3.15B | D+ | ||
+6.42% | 2.59B | - | - | |
-8.29% | 1.79B | D+ | ||
+1.72% | 1.74B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VITR Stock
- Ratings Vitrolife AB